Morgan Stanley analyst Matthew Harrison maintained a Sell rating on Bluebird Bio (BLUE – Research Report) today and set a price target of $4.00. The company’s shares opened today at $6.16.
Harrison covers the Healthcare sector, focusing on stocks such as Moderna, Gilead Sciences, and Editas Medicine. According to TipRanks, Harrison has an average return of 7.9% and a 53.46% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Bluebird Bio with a $6.33 average price target.
See today’s best-performing stocks on TipRanks >>
BLUE market cap is currently $514.1M and has a P/E ratio of -1.02.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLUE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
Read More on BLUE:
